RecruitingACTRN12624000269538

Improving care of attention deficit hyperactivity disorder (ADHD) in people who use drugs

Managing substance use disorder (SUD) in the presence of Attention Deficit Hyperactivity Disorder (ADHD): does active management of ADHD improve outcomes in terms of reduced drug use and improved quality of life?


Sponsor

Alcohol and Drug Research Innovation Agenda (ADRIA)

Enrollment

80 participants

Start Date

Jan 3, 2024

Study Type

Interventional

Conditions

Summary

ADHD is a common neurodevelopmental disorder defined by the persistence of dysregulated attention, activity and impulsivity. The incidence of ADHD in childhood is 6-7%. Some symptoms improve in adolescence, but 2–4% of adults continue to meet the diagnostic criteria. ADHD is recognised in 3 to 4 times as many people seeking help for substance use disorder (SUD) as in the general population. Adults with ADHD who use drugs are often misdiagnosed and cannot access effective, targeted, multidisciplinary care. Individual specialists and specialist services will not treat ADHD in the presence of SUD. This project aims to demonstrate that recognition of ADHD and active management significantly improve quality of life and reduce substance use in people seeking help for SUD.


Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

ADHD (attention deficit hyperactivity disorder) is a condition that makes it hard to focus, stay still, and control impulses. It affects around 2-4% of adults, but is found in much higher rates — three to four times more common — among people who are also dealing with a substance use disorder. Yet these two conditions are rarely treated together, and many individuals fall through the cracks of the healthcare system. This study in the Goulburn Valley region aims to show that when ADHD is properly recognised and actively managed in people seeking help for drug or alcohol problems, quality of life improves and substance use decreases. Participants who screen positive for ADHD and are confirmed through clinical interview will receive targeted, multidisciplinary care that addresses both conditions simultaneously. You may be eligible if you are 18 or older, live in the Goulburn Valley Health catchment area, and score high on the ADHD self-report scale. People with severe neurological conditions, uncontrolled cardiovascular disease, glaucoma, or psychosis are not eligible. This study addresses a significant gap in how two highly connected health issues are currently managed.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

The subjects will be divided randomly on enrolment into tow groups. Group A will be immediately be provided with additional services including case management, counselling, access to ADHD coaching,

The subjects will be divided randomly on enrolment into tow groups. Group A will be immediately be provided with additional services including case management, counselling, access to ADHD coaching, and a mental health review with a psychiatrist. A research nurse will provide case management. All contacts and reviews (including telehealth review) will be recorded. Group B will be offered all the additional services after 6 months of treatment as usual. Treatment as usual consists of assessment by an addiction medicine specialist, psychiatric registrar or psychiatrist who prescribes medication, provides psychoeducation and reviews the patients as required. The additional services include: (a) case management by a nurse or alcohol and other drug case worker includes monitoring adherence and issuing reminders to ensure partiipation (b) access to coaching by a qualified ADHD coach (typically 10 weekly one hour sessions) (c) formal review of comorbid mental health issues by an independent psychiatrist (d) regular review (at least monthly) by the research nurse or an addiction medicine or addiction psychiatry consultant


Locations(1)

VIC, Australia

View Full Details on ANZCTR

For the most up-to-date information, visit the official listing.

Visit

ACTRN12624000269538


Related Trials